Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $69.50 USD
Change Today 0.00 / 0.00%
Volume 0.0
AZNCF On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 8:10 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2 Kingdom Street

London, W2 6BD

United Kingdom

Phone: 44 20 7604 8000

Fax: 44 20 7604 8151

potential treatment for Alzheimer’s. Also in 2014, the company secured approval for Movantik (naloxegol) in the U.S. and Moventig in the EU for the treatment of opioid-induced constipation. Movantik/Moventig approval Movantik/Moventig, which was approved in the U.S. in September 2014 and in the EU in December 2014, is the orally administered, once daily peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved for the treatment of opioid induced constipation (OIC) in adult patients who have had an inadequate response to laxatives. Movantik/Moventig acts directly on the mu-opioid receptors in the gut, which cause OIC when opioids are used, and constitutes an important and novel option for opioid users. Movantik/Moventig was developed using Nektar Therapeutics’ oral small molecule polymer conjugate technology as part of a 2009 licence agreement with Nektar Therapeutics. In 2014, the company signed an agreement with Lilly for the joint development and commercialisation of AZD3293, its oral beta secretase cleaving enzyme (BACE) inhibitor being developed as a potential treatment for Alzheimer’s disease. The company has collaborations with the University of Cambridge (focusing on advancing research and development in neurodegenerative diseases), the Karolinska Institutet (Sweden), the Banner Alzheimer’s Institute (US), the National Institute of Radiological Sciences (Japan), Vanderbilt University (US) (focusing on psychosis and other neuropsychiatric symptoms associated with major brain diseases, such as Alzheimer’s disease and schizophrenia), an alliance of several academic centres (known as ‘A5’), and Tufts University (US) (focusing on brain diseases and disorders, including Alzheimer’s disease, Parkinson’s disease and autism spectrum disorders). The company also joined the Medical Research Council Dementias Platform UK (DPUK), a large public-private partnership to accelerate and share dementias research. The company’s anaesthesia portfolio consists of various compounds, including an intravenous general anaesthetic/sedative and local anaesthetics available in different formulations, including injectables, creams, gels, sprays and suppositories. Biologics are an emerging treatment for pain control and the company is exploring treatments in focused pain areas where patients can be selected based on symptomatic characteristics. The company is developing AZD5213, a Phase II histamine-3 receptor antagonist for neuropathic pain. Gastrointestinal Marketed Products Entocort (budesonide) is a locally-acting corticosteroid used to treat inflammatory bowel disease. Losec/Prilosec (omeprazole) is used for the short- and long-term treatment of acid-related diseases. Nexium (esomeprazole magnesium) is a proton pump inhibitor used to treat acid-related diseases. Significant Events In March 2015, AstraZeneca has entered into an alliance with Singapore's Agency for Science, Technology and Research, National University Heart Centre, Singapore (NUHCS), and the National University of Singapore. In March 2015, AstraZeneca has announced a co-commercialization agreement with Daiichi Sankyo Inc. for MOVANTIK, a once-daily oral peripherally-acting mu-opioid receptor antagonist, or PAMORA, for the treatment of opioid-induced constipation, or OIC, in adults with chronic non-cancer pain, in the U.S. History The company was founded 1992. It was incorporated in England and Wales in 1992 under the Companies Act 1985. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZNCF:US $69.50 USD 0.00

AZNCF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $58.54 USD +0.30
Bristol-Myers Squibb Co $64.50 USD -1.26
Eli Lilly & Co $72.65 USD -1.22
Novo Nordisk A/S kr372.00 DKK -4.80
Valeant Pharmaceuticals International Inc C$250.21 CAD -6.46
View Industry Companies
 

Industry Analysis

AZNCF

Industry Average

Valuation AZNCF Industry Range
Price/Earnings 71.8x
Price/Sales 3.4x
Price/Book 4.5x
Price/Cash Flow 71.7x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.